Hypermarcas (OTCMKTS:HYPMY) Trading Up 8.6% – Should You Buy?

Hypermarcas (OTCMKTS:HYPMY) shares shot up 8.6% during mid-day trading on Tuesday . The stock traded as high as $4.8850 and last traded at $4.8850. 2,383 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 57,525 shares. The stock had previously closed at $4.50.

Analyst Upgrades and Downgrades

Separately, Scotiabank raised Hypermarcas to a “strong-buy” rating in a report on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, Hypermarcas has a consensus rating of “Strong Buy”.

Hypermarcas Trading Up 3.2%

The company has a market capitalization of $2.94 billion, a price-to-earnings ratio of 22.11 and a beta of 0.82. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26. The firm has a fifty day moving average price of $4.24 and a 200-day moving average price of $4.38.

Hypermarcas (OTCMKTS:HYPMY) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.12 earnings per share (EPS) for the quarter. Hypermarcas had a net margin of 11.28% and a return on equity of 6.19%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.